CXCL8 and lung adenocarcinoma: We hypothesized that if regulated at the level of LINC00261 and CDK1, inhibiting IL-8 secretion and remodeling the tumor immune microenvironment might reverse immune resistance and improve the effectiveness of lung adenocarcinoma patients receiving immunotherapy.